Shots:
- Japan’s MHLW received MAA of finerenone for HF pts having a left ventricular ejection fraction (LVEF) of ≥40%, i.e. mildly reduced (HFmrEF) or preserved LVEF (HFpEF). Regulatory review is ongoing in the US, EU & China, with global filings planned
- Application was backed by P-III (FINEARTS-HF) trial, a part of P-III (MOONRAKER, n>15000) study, where FINEARTS-HF assessed finerenone (QD) vs PBO in pts (n=~6000) with HF as well as LVEF of ≥40%, who received diuretic therapy for ≥30 days before randomization
- Study showed improved CV outcomes. Data was presented at ESC Congress 2024 & was published in The NEJM
Ref: Bayer | Image: Bayer
Related News:- Bayer Submits MAA of Finerenone to the EMA for Heart Failure (HF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
